This subproject is one of many research subprojects utilizing theresources provided by a Center grant funded by NIH/NCRR. The subproject andinvestigator (PI) may have received primary funding from another NIH source,and thus could be represented in other CRISP entries. The institution listed isfor the Center, which is not necessarily the institution for the investigator.The purpose of this research is to identify the pharmacokinetic and pharmacodynamic profile of PS341 in patients with advanced malignancy and varying degrees of liver dysfunction. The research will also evaluate the safety, tolerability, and the maximum tolerated dose of PS341 for patients with varying degrees of liver dysfunction.
Showing the most recent 10 out of 459 publications